United States: As this Ebola-like virus which is called Marburg Virus which is spreading in the nations worldwide and which really can be a concerning matter for the Health Officials. However, the authorities are looking to develop a vaccine shot to lessen the impact of this virus. So, here’s some words from the mouth of one of vaccine developers.
Hi, it’s Ashleigh in London. I have been searching for the reasons that create the strange problem of getting vaccines for some deadly diseases as Marburg virus. But first…
A packed train in Hamburg, a medical student fresh off the plane after a long flight from Rwanda, a small mountainous country struggling to come to terms with a first outbreak of a virulent haemorrhagic fever, and now Europe faces the grim prospect that a disease that kills anything up to 88% of those it infects.
Not the plot of a low-grade horror flick, but reality. It’s the news out of Germany and Rwanda this week.
As reported by Bloomberg.com, the patient actually turned out to be negative, but the scare has alerted attention to the Marburg like virus in Rwanda which thus far has killed 11 persons and has infected 36.
There is no approved vaccine for Marburg, and there are currently no therapies that are lawful to treat the disease. Or does Changing that present a strange paradox? Nobody would want to have a flare out of a disease that is very rare and highly fatal. But those outbreaks could help actually to check if the vaccines and the drugs are effective against the virus.
Mark Feinberg the chief executive officer of IAVI a non-profit organisation that develops and manufactures vaccines and antibodies drugs understands only too well the need to act swiftly when outbreaks happen. He was with pharma giant Merck prior to the current company where he played a critical role in ensuring the delivery of a vaccine for the Ebola virus outbreak of 2014-2016. They helped to approve the first Ebola shot of a vaccine.
This time possible vaccines from Mapp Biopharmaceutical and Sabin Vaccine Institute with an experimental vaccine may be tried in Rwanda. Both have mentioned that they are talking to the Rwandan government or any other relevant partners in getting the products to the ground.
But it’s not an easy task. Clinical trial usually takes months to set up and the years to complete and how do you do that for an outbreak that could be over imminently?
For Ebola, studies were initially started in Liberia and Sierra Leone but public health responses brought infections under the control and the meaning it wasn’t possible to do an efficacy trial says Feinberg.
Leave a Reply